Issue link: https://www.e-digitaleditions.com/i/1491587
Technical articles discuss biological models to inform research and development of inhalation products and a novel pathway known as excipient enhanced growth, which is progressing through toxicological studies and showing promise for the treatment of both asthma and lung cancer. 2 February 2023 Inhalation Inhalation (ISSN 1937-0717 print; ISSN 1940-414X online) is published seven times per year in January, February, April, June, August, October and December by Whipsnade and Loophole, LLC, P.O. Box 27092, Minneapolis, MN 55427 US. w w w . i n h a l a t i o n m a g . c o m February 2023 Volume 17 Number 1 The cover photo shows a dry powder inhaler with a hypromellose-origin cap- sule, specifically developed for inhaled drug delivery. Courtesy of Qualicaps ® , Avenida Monte Valdelatas, 4, 28108 Madrid, Spain. Tel: +34 916 630 800, www.qualicaps.com product development/contract testing 10 Application of biological models to inform research and development of inhalation products Juhura Gania Almazi and Hui Xin Ong 21 Issue focus: Product development/Contract testing 26 Excipient enhanced growth (EEG): Expanding delivery options for the treatment of lung diseases Maureen Kadleck, Joseph Churchman and Bryce Beverlin II formulation development/excipients 32 Special section: Formulation development/Excipients additional features 6 Cross-industry organizations: The International Society for Aerosols in Medicine (ISAM): 2022 highlights and a preview of 2023 activities Barbara Rothen-Rutishauser 9 Previewing RDD® Europe 2023 36 Back pages: Nestlé reconsidering only FDA-approved peanut allergy drug for children due to slow uptake Food allergy bravery clinic helps children overcome anxiety departments 8 Industry news 8 Respiratory medicine news 34 Calendar 35 White papers and webinars